Sort by
Refine Your Search
-
supplements/variations). Develop and maintain knowledge of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Good Clinical Practice (GCP), Good
-
research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human
-
direct applications to human health and performance. The postdoc will join a collaborative team led by Dr. C.J. Hasson (Department of Physical Therapy, Movement and Rehabilitation Sciences) and Dr. Peter
-
About the Opportunity About the Institute Do you want to be part of an exciting new Institute focused on combining human and machine intelligence into working AI solutions? We are launching a
-
to prioritize and deliver Excellent leadership and relationship skills Ability to collaborate cross functionally Ability to meet deadlines Additional Information Applicants should submit the following application
-
intervention. We are performing complementary human and mouse studies to evaluate plasma biomarkers in combination with retinal vascular health as biomarkers for ADRD. We are seeking a highly motivated
-
or escalate issues as appropriate Values and behaviours consistent with CSL’s High ethical standards as well as personal credibility Ability to prioritize and deliver Excellent leadership and relationship
-
investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy
-
clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney
-
investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy